Altrius Capital Management Inc lifted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 4.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 225,819 shares of the pharmaceutical company's stock after acquiring an additional 9,819 shares during the quarter. GSK accounts for about 2.1% of Altrius Capital Management Inc's investment portfolio, making the stock its 8th biggest position. Altrius Capital Management Inc's holdings in GSK were worth $8,748,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Parkside Financial Bank & Trust grew its stake in GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 818 shares in the last quarter. Lee Danner & Bass Inc. acquired a new position in GSK in the fourth quarter worth about $39,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in GSK in the fourth quarter worth about $40,000. Atala Financial Inc acquired a new position in GSK in the fourth quarter worth about $45,000. Finally, Whipplewood Advisors LLC acquired a new position in GSK in the fourth quarter worth about $46,000. 15.74% of the stock is owned by hedge funds and other institutional investors.
GSK Stock Performance
Shares of NYSE GSK traded up $0.19 during midday trading on Monday, hitting $38.26. 4,858,811 shares of the company's stock were exchanged, compared to its average volume of 4,935,240. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58. The stock's 50 day moving average price is $38.58 and its 200-day moving average price is $36.85. The firm has a market cap of $78.33 billion, a P/E ratio of 19.72, a PEG ratio of 1.33 and a beta of 0.52. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67.
GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. During the same quarter in the previous year, the company earned $0.43 earnings per share. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. Equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.
GSK Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be issued a $0.4216 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.41%. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is currently 87.11%.
Wall Street Analysts Forecast Growth
GSK has been the subject of a number of research reports. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. BNP Paribas initiated coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. Hsbc Global Res upgraded GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, Berenberg Bank restated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $37.38.
Check Out Our Latest Research Report on GSK
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
